|
|
Office Locations:
|
29 Newbury Street, 301
Boston, MA 02116
Phone: 617-585-2000
Fax: 617-859-2891
| |
|
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Founded in 2007, Third Rock Ventures has over $1.3 billion under management for exclusive investment in life-sciences, primarily in biotechnology, biopharmaceutical, and medical device companies. The firm's strategy is to lead investing rounds and continue with a significant stake in uniquely innovative life sciences businesses, making an initial investment of up to $35 million. Third Rock was founded by four ex-Millennium Pharma executives, including former Millennium CEO, Mark Levin. The firm announced the final closing of Fund III (March 2013), raising $516 million in an oversubscribed fund. Third Rock announced the closing of Third Rock Ventures IV, LP October of 2016, raising $616 million in an oversubscribed fund. The firm has 58 portfolio companies. Third Rock Ventures announced (June 2022) the closing of Third Rock Ventures Fund VI, raising $1.1 billion
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
